semaglutide type 2 diabetes (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss Type 2 diabetes: New Ozempic

This triple-action approach makes it one of the most comprehensive peptides for optimizing metabolism, weight loss, and overall energy balance

Semaglutide is a GLP-1 receptor agonist that lowers blood sugar by stimulating insulin release, but hypoglycemia risk varies by individual health status and medication combinations

Planning a pregnancy on a GLP-1

A wave of low-cost generic drugs is sparking a price war in the weight-loss medication market, turning India into a testing ground for Novo Nordisks semaglutide as its patent expires.

Academic pharmacist Nataly Martini reviews type 2 diabetes, focusing on how evolving treatment paradigms translate into practical, patient-centred and equity-informed approaches to care